Changing patterns of bacterial profile and antimicrobial resistance in high-risk patients during the COVID-19 pandemic at a tertiary oncology hospital
Archives of Microbiology · 2024
DOI: 10.1007/s00203-024-03965-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Microbiology, 2024. Verfasst von Rasha M Abdel-Hamid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt. rasha.elgyar@nci.cu.edu.eg. Hauptthemen laut MEDLINE: COVID-19, Tertiary Care Centers, Anti-Bacterial Agents, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
The widespread evolution of phenotypic resistance in clinical isolates over the years, coupled with the COVID-19 pandemic onset, has exacerbated the global challenge of antimicrobial resistance. This study aimed to explore changes in bacterial infection patterns and antimicrobial resistance during the COVID-19 pandemic. This study involved the periods before and during COVID-19: the pre-pandemic and pandemic eras. The surveillance results of bacterial isolates causing infections in cancer patients at an Egyptian tertiary oncology hospital were retrieved. The Vitek®2 or Phoenix systems were utilized for species identification and susceptibility testing. Statistical analyses were performed comparing microbiological trends before and during the pandemic. Out of 2856 bacterial isolates, Gram-negative bacteria (GNB) predominated (69.7%), and Gram-positive bacteria (GPB) comprised 30.3% of isolates. No significant change was found in GNB prevalence during the pandemic (P = 0.159). Elevated rates of Klebsiella and Pseudomonas species were demonstrated during the pandemic, as was a decrease in E. coli and Acinetobacter species (P < 0.001, 0.018, < 0.001, and 0.046, respectively) in hematological patients. In surgical patients, Enterobacteriaceae significantly increased (P = 0.012), while non-fermenters significantly decreased (P = 0.007). GPB species from either hematological or surgical wards exhibited no notable changes during the pandemic. GNB resistance increased in hematological patients to carbapenems, amikacin, and tigecycline and decreased in surgical patients to amikacin and cefoxitin (P < 0.001, 0.010, < 0.001, < 0.001, and 0.016, respectively). The study highlights notable shifts in the microbial landscape during the COVID-19 pandemic, particularly in the prevalence and resistance patterns of GNB in hematological and surgical wards.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt. rasha.elgyar@nci.cu.edu.eg.
- Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Microbiology and Immunology Department, Faculty of Pharmacy, Ahram Canadian University, Cairo, Egypt.
Zitieren
APA
Abdel-Hamid, R. M., El-Mahallawy, H. A., Allam, R. M., Zafer, M. M., & Elswify, M. (2024). Changing patterns of bacterial profile and antimicrobial resistance in high-risk patients during the COVID-19 pandemic at a tertiary oncology hospital. Archives of Microbiology. https://doi.org/10.1007/s00203-024-03965-x
Vancouver
Abdel-Hamid RM, El-Mahallawy HA, Allam RM, Zafer MM, Elswify M. Changing patterns of bacterial profile and antimicrobial resistance in high-risk patients during the COVID-19 pandemic at a tertiary oncology hospital. Archives of Microbiology. 2024. doi:10.1007/s00203-024-03965-x
BibTeX
@article{AbdelHamid2024,
author = {Abdel-Hamid, Rasha M and El-Mahallawy, Hadir A and Allam, Rasha M and Zafer, Mai M and Elswify, Marwa},
title = {Changing patterns of bacterial profile and antimicrobial resistance in high-risk patients during the COVID-19 pandemic at a tertiary oncology hospital},
journal = {Archives of Microbiology},
year = {2024},
doi = {10.1007/s00203-024-03965-x}
}
EUVIMED